Literature DB >> 22460895

Cancer: Clinical trials unite mice and humans.

Leisa Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22460895     DOI： 10.1038/483546a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  LKB1 modulates lung cancer differentiation and metastasis.

Authors:  Hongbin Ji; Matthew R Ramsey; D Neil Hayes; Cheng Fan; Kate McNamara; Piotr Kozlowski; Chad Torrice; Michael C Wu; Takeshi Shimamura; Samanthi A Perera; Mei-Chih Liang; Dongpo Cai; George N Naumov; Lei Bao; Cristina M Contreras; Danan Li; Liang Chen; Janakiraman Krishnamurthy; Jussi Koivunen; Lucian R Chirieac; Robert F Padera; Roderick T Bronson; Neal I Lindeman; David C Christiani; Xihong Lin; Geoffrey I Shapiro; Pasi A Jänne; Bruce E Johnson; Matthew Meyerson; David J Kwiatkowski; Diego H Castrillon; Nabeel Bardeesy; Norman E Sharpless; Kwok-Kin Wong
Journal:  Nature       Date:  2007-08-05       Impact factor: 49.962

Review 3.  Prognosis and reevaluation of lung cancer by positron emission tomography imaging.

Authors:  Jeremy J Erasmus; Eric Rohren; Stephen G Swisher
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

4.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Authors:  Zhao Chen; Katherine Cheng; Zandra Walton; Yuchuan Wang; Hiromichi Ebi; Takeshi Shimamura; Yan Liu; Tanya Tupper; Jing Ouyang; Jie Li; Peng Gao; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Abigail Altabef; Shumei Wang; Charles Lee; Yuji Nakada; Christopher G Peña; Yanping Sun; Yoko Franchetti; Catherine Yao; Amy Saur; Michael D Cameron; Mizuki Nishino; D Neil Hayes; Matthew D Wilkerson; Patrick J Roberts; Carrie B Lee; Nabeel Bardeesy; Mohit Butaney; Lucian R Chirieac; Daniel B Costa; David Jackman; Norman E Sharpless; Diego H Castrillon; George D Demetri; Pasi A Jänne; Pier Paolo Pandolfi; Lewis C Cantley; Andrew L Kung; Jeffrey A Engelman; Kwok-Kin Wong
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

5.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

6.  Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

Authors:  Klaus P Hoeflich; Mark Merchant; Christine Orr; Jocelyn Chan; Doug Den Otter; Leanne Berry; Ian Kasman; Hartmut Koeppen; Ken Rice; Nai-Ying Yang; Stefan Engst; Stuart Johnston; Lori S Friedman; Marcia Belvin
Journal:  Cancer Res       Date:  2011-11-14       Impact factor: 12.701

7.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.

Authors:  Mallika Singh; Anthony Lima; Rafael Molina; Patricia Hamilton; Anne C Clermont; Vidusha Devasthali; Jennifer D Thompson; Jason H Cheng; Hani Bou Reslan; Calvin C K Ho; Timothy C Cao; Chingwei V Lee; Michelle A Nannini; Germaine Fuh; Richard A D Carano; Hartmut Koeppen; Ron X Yu; William F Forrest; Gregory D Plowman; Leisa Johnson
Journal:  Nat Biotechnol       Date:  2010-05-23       Impact factor: 54.908

Review 8.  Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.

Authors:  Thierry Berghmans; Michèle Dusart; Marianne Paesmans; Claude Hossein-Foucher; Irene Buvat; Catherine Castaigne; Arnaud Scherpereel; Céline Mascaux; Michel Moreau; Martine Roelandts; Stéphane Alard; Anne-Pascale Meert; Edward F Patz; Jean-Jacques Lafitte; Jean-Paul Sculier
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

9.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.

Authors:  Hongbin Ji; Zhenxiong Wang; Samanthi A Perera; Danan Li; Mei-Chih Liang; Sara Zaghlul; Kate McNamara; Liang Chen; Mitchell Albert; Yanping Sun; Ruqayyah Al-Hashem; Lucian R Chirieac; Robert Padera; Roderick T Bronson; Roman K Thomas; Levi A Garraway; Pasi A Jänne; Bruce E Johnson; Lynda Chin; Kwok-Kin Wong
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

Review 10.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  C Mascaux; N Iannino; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; S Noel; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640
View more
  2 in total

1.  Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model.

Authors:  Satyan S Kalkunte; Stefan Neubeck; Wendy E Norris; Shi-Bin Cheng; Stefan Kostadinov; Dang Vu Hoang; Aftab Ahmed; Ferdinand von Eggeling; Zahir Shaikh; James Padbury; Goran Berg; Anders Olofsson; Udo R Markert; Surendra Sharma
Journal:  Am J Pathol       Date:  2013-09-10       Impact factor: 4.307

Review 2.  Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?

Authors:  Piet Borst
Journal:  Open Biol       Date:  2012-05       Impact factor: 6.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.